AFPep: an anti-breast cancer peptide that is orally active

被引:27
作者
Bennett, James A. [1 ]
DeFreest, Lori
Anaka, Ikenna
Saadati, Hamid
Balulad, Sujata
Jacobson, Herbert I.
Andersen, Thomas T.
机构
[1] Albany Med Coll, Ctr Immunol & Microbial Dis MC 22, Albany, NY 12208 USA
[2] Albany Med Coll, Ctr Cardiovasc Sci, Albany, NY 12208 USA
[3] Albany Med Coll, Dept Obstet Gynecol & Reprod Sci, Albany, NY 12208 USA
关键词
animal models; breast cancer; oral availability; prevention; therapy; toxicity;
D O I
10.1007/s10549-005-9140-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. We have synthesized a cyclic nonapeptide (AFPep) that is effective, after being administered by parenteral routes, for the treatment or the prevention of breast cancer. To test the hypothesis that AFPep remains safe and efficacious after oral administration, three different whole-animal bioassays were utilized, and the mechanism by which AFPep functions was investigated. Methods. Using a human breast cancer xenograft model in mice for therapeutic activity, a carcinogen-induced breast cancer model in rats for prevention efficacy, and a mouse uterus growth inhibition model of anti-estrogenic activity, AFPep was administered by oral gavage (p.o.) and its effects compared to those following intraperitoneal (i.p.) and subcutaneous (s.c.) administration. Toxicity studies evaluated body weights and organ weights in mice and rats receiving AFPep. Preliminary mechanistic studies were carried out in T47D human breast cancer cells growing in culture and evaluated the effect of AFPep on estrogen-stimulated cell growth, phosphorylation of the estrogen receptor (ER), and on level of ER-related kinases. Results. Orally administered AFPep stopped the growth of human tumor xenografts in mice, decreased the incidence and multiplicity of breast cancers in carcinogen-exposed rats, and inhibited the estrogen-stimulated growth of mouse uteri. In each of these systems, orally administered AFPep produced an effect similar to that obtained for AFPep administered by either i.p or s.c. routes. In rodents, no evidence of toxicity was seen for the peptide, even at very high doses. In culture, AFPep inhibited the estrogen-stimulated growth, but not the basal growth, of T47D cells, and it inhibited the estrogen-stimulated phosphorylation of Serine 118 in the ER of these cells, which was not explainable by early changes in ER-related kinases. Conclusions. Chronic oral administration of AFPep appears to be safe and effective for the treatment or prevention of breast cancer in animal models.
引用
收藏
页码:133 / 141
页数:9
相关论文
共 19 条
[1]  
Bennett JA, 1998, CLIN CANCER RES, V4, P2877
[2]   Similarity between natural and recombinant human alpha-fetoprotein as inhibitors of estrogen-dependent breast cancer growth [J].
Bennett, JA ;
Semeniuk, DJ ;
Jacobson, HI ;
Murgita, RA .
BREAST CANCER RESEARCH AND TREATMENT, 1997, 45 (02) :169-179
[3]   A peptide derived from α-fetoprotein prevents the growth of estrogen-dependent human breast cancers sensitive and resistant to tamoxifen [J].
Bennett, JA ;
Mesfin, FB ;
Andersen, TT ;
Gierthy, JF ;
Jacobson, HI .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (04) :2211-2215
[4]  
CHAABNER BA, 2001, PHARMACOL BASIS THER, P1389
[5]   ALPHA-FETOPROTEIN - A REVIEW [J].
CRANDALL, BF ;
LAU, HL .
CRC CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 1981, 15 (02) :127-185
[6]   Synthetic peptide derived from α-fetoprotein inhibits growth of human breast cancer:: investigation of the pharmacophore and synthesis optimization [J].
DeFreest, LA ;
Mesfin, FB ;
Joseph, L ;
McLeod, DJ ;
Stallmer, A ;
Reddy, S ;
Balulad, SS ;
Jacobson, HI ;
Andersen, TT ;
Bennett, JA .
JOURNAL OF PEPTIDE RESEARCH, 2004, 63 (05) :409-419
[7]  
GOETZ MP, 2005, CANC PRINCIPLES PRAC, P457
[8]  
GRUBBS CJ, 1983, J NATL CANCER I, V71, P625
[9]  
GRUBBS CJ, 1986, ANTICANCER RES, V6, P1395
[10]   AUTOMATED ALLYL CLEAVAGE FOR CONTINUOUS-FLOW SYNTHESIS OF CYCLIC AND BRANCHED PEPTIDES [J].
KATES, SA ;
DANIELS, SB ;
ALBERICIO, F .
ANALYTICAL BIOCHEMISTRY, 1993, 212 (02) :303-310